T\u0131bbi Onkoloji Uzman\u0131 Do\u00e7. Dr. Ferhat Ferhato\u011flu, \u201cKanser alan\u0131nda geli\u015ftirilen yeni a\u015f\u0131 yakla\u015f\u0131mlar\u0131, hastal\u0131\u011f\u0131n olu\u015fmadan \u00f6nlenmesine y\u00f6nelik \u00f6nemli bir potansiyel sunuyor. Bu yakla\u015f\u0131m \u00f6zellikle y\u00fcksek riskli bireyler i\u00e7in dikkat \u00e7ekici bir geli\u015fme olarak de\u011ferlendiriliyor. Yeni a\u015f\u0131 yakla\u015f\u0131mlar\u0131 umut vadediyor\u201d dedi.<\/p>\n
Kanserin ilerleyen evrelerde tedavisinin zorla\u015fmas\u0131n\u0131n en \u00f6nemli nedenlerinden birinin t\u00fcm\u00f6r h\u00fccrelerinin genetik olarak stabil olmamas\u0131 oldu\u011funu belirten Yeditepe \u00dcniversitesi Hastaneleri T\u0131bbi Onkoloji Uzman\u0131 Do\u00e7. Dr. Ferhat Ferhato\u011flu \u201cBu durum kanser h\u00fccrelerinin zaman i\u00e7inde farkl\u0131 \u00f6zellikler kazanmas\u0131na yol a\u00e7\u0131yor. Bu s\u00fcreci biyolojik evrime benzetebiliriz. Nas\u0131l ki mutasyonlar yeni t\u00fcrlerin ortaya \u00e7\u0131kmas\u0131na neden oluyorsa, kanser de benzer \u015fekilde dallanarak ilerleyen dinamik bir s\u00fcre\u00e7tir\u201d ifadelerini kulland\u0131.<\/p>\n
Do\u00e7. Dr. Ferhato\u011flu, \u201cKanser a\u015f\u0131lar\u0131, son y\u0131llarda imm\u00fcnoterapinin en dikkat \u00e7eken alanlar\u0131ndan biri olarak \u00f6ne \u00e7\u0131k\u0131yor. Bu a\u015f\u0131lar genel olarak ikiye ayr\u0131l\u0131yor: HPV ve HBV gibi vir\u00fcslere kar\u015f\u0131 geli\u015ftirilen koruyucu a\u015f\u0131lar ve do\u011frudan kanser h\u00fccrelerini hedef alan tedavi edici a\u015f\u0131lar. Tedavi edici a\u015f\u0131lar, ba\u011f\u0131\u015f\u0131kl\u0131k sistemini aktive ederek kanser h\u00fccrelerini ortadan kald\u0131rmay\u0131 ama\u00e7l\u0131yor. Ancak bu alanda geli\u015ftirilen yeni bir yakla\u015f\u0131m kanserin do\u011fas\u0131na daha derin bir bak\u0131\u015f sunarak dikkat \u00e7ekiyor\u201d diye konu\u015ftu.<\/p>\n
\u2018KANSER H\u00dcCRELER\u0130 TEDAV\u0130YE D\u0130REN\u00c7 GEL\u0130\u015eT\u0130REB\u0130L\u0130YOR\u2019<\/p>\n
T\u00fcm\u00f6r h\u00fccreleri aras\u0131ndaki bu genetik farkl\u0131l\u0131klar\u0131n, de\u011fi\u015fen \u00e7evresel ko\u015fullara uyum sa\u011flama ve tedavilere diren\u00e7 geli\u015ftirme yetene\u011fini beraberinde getirdi\u011fine dikkat \u00e7eken Do\u00e7. Dr. Ferhato\u011flu, kemoterapi, radyoterapi ve cerrahi gibi y\u00f6ntemlerin baz\u0131 durumlarda kanseri tamamen ortadan kald\u0131rmakta yetersiz kalabildi\u011fini vurgulad\u0131. Do\u00e7. Dr. Ferhato\u011flu, \u201cTedaviden sa\u011f kurtulan h\u00fccreler zaman i\u00e7inde \u00e7o\u011falarak daha diren\u00e7li hale gelebiliyor. Bu nedenle daha hedefe y\u00f6nelik yeni tedavi stratejilerine ihtiya\u00e7 duyuluyor\u201d ifadelerini kulland\u0131.<\/p>\n
\u2018HEDEF: KANSER\u0130N K\u00d6K\u00dcN\u00dc ORTADAN KALDIRMAK\u2019<\/p>\n
Yeni geli\u015ftirilen yakla\u015f\u0131m\u0131n, kanserin k\u00f6k\u00fcn\u00fc olu\u015fturan mutasyonlar\u0131n hedef al\u0131nmas\u0131na dayand\u0131\u011f\u0131n\u0131 belirten Do\u00e7. Dr. Ferhato\u011flu, bu mutasyonlar\u0131n bir a\u011fac\u0131n g\u00f6vdesi gibi d\u00fc\u015f\u00fcn\u00fclebilece\u011fini ifade etti. \u2018E\u011fer bu k\u00f6k mutasyonlar\u0131 tespit edebilirsek, ba\u011f\u0131\u015f\u0131kl\u0131k sistemini bu hedeflere kar\u015f\u0131 uyararak kanseri daha olu\u015fmadan engellemek m\u00fcmk\u00fcn olabilir\u2019 diyen Do\u00e7. Dr. Ferhato\u011flu, \u00f6zellikle akci\u011fer kanseri a\u00e7\u0131s\u0131ndan y\u00fcksek riskli bireylerde bu yakla\u015f\u0131m\u0131n \u00f6nemli bir potansiyel ta\u015f\u0131d\u0131\u011f\u0131n\u0131 s\u00f6yledi.<\/p>\n
\u2018TRACERX \u00c7ALI\u015eMASI YEN\u0130 B\u0130R KAPI A\u00c7TI\u2019<\/p>\n
2014 y\u0131l\u0131nda ba\u015flat\u0131lan TRACERx \u00e7al\u0131\u015fmas\u0131n\u0131n, kanserin bir \u2018evrim a\u011fac\u0131\u2019 gibi geli\u015fti\u011fini ve t\u00fcm t\u00fcm\u00f6r h\u00fccrelerinde ortak olan k\u00f6k mutasyonlar\u0131n varl\u0131\u011f\u0131n\u0131 ortaya koydu\u011funu belirten Do\u00e7. Dr. Ferhato\u011flu, bu bulgular\u0131n y\u00fcksek riskli bireyler i\u00e7in geli\u015ftirilen ilk akci\u011fer kanseri a\u015f\u0131s\u0131 LungVax\u2019\u0131n temelini olu\u015fturdu\u011funu ifade etti.<\/p>\n
\u2018N\u00dcKS\u00dcN \u00d6NLENMES\u0130 HEDEFLEN\u0130YOR\u2019<\/p>\n
Oxford\u2019da y\u00fcr\u00fct\u00fclecek LungVax \u00e7al\u0131\u015fmas\u0131n\u0131n, \u00f6zellikle erken evre k\u00fc\u00e7\u00fck h\u00fccreli d\u0131\u015f\u0131 akci\u011fer kanseri nedeniyle ameliyat edilmi\u015f hastalarda kanserin tekrar\u0131n\u0131 \u00f6nlemeyi ama\u00e7lad\u0131\u011f\u0131n\u0131 belirten Do\u00e7. Dr. Ferhato\u011flu, \u201cBu a\u015f\u0131 ile t\u00fcm\u00f6rlerde ortak bulunan neoantijenler hedef al\u0131narak g\u00fc\u00e7l\u00fc bir ba\u011f\u0131\u015f\u0131kl\u0131k yan\u0131t\u0131 olu\u015fturulmas\u0131 hedefleniyor. B\u00f6ylece kanser h\u00fccreleri hen\u00fcz klinik olarak ortaya \u00e7\u0131kmadan ortadan kald\u0131r\u0131labilir\u201d dedi.<\/p>\n
\u2018COVID-19 A\u015eILARINA BENZER TEKNOLOJ\u0130\u2019<\/p>\n
Geli\u015ftirilen yakla\u015f\u0131m\u0131n, COVID-19 d\u00f6neminde kullan\u0131lan mRNA a\u015f\u0131lar\u0131na benzer bir mekanizmaya dayand\u0131\u011f\u0131n\u0131 ifade eden Do\u00e7. Dr. Ferhato\u011flu, ba\u011f\u0131\u015f\u0131kl\u0131k sisteminin hedef almas\u0131 gereken neoantijenler arac\u0131l\u0131\u011f\u0131yla uyar\u0131ld\u0131\u011f\u0131n\u0131 belirtti. \u0130lk a\u015famada 40 hastal\u0131k bir grupta g\u00fcvenlik ve etkinlik de\u011ferlendirilece\u011fini, \u00e7al\u0131\u015fman\u0131n 2026 yaz\u0131nda ba\u015flanmas\u0131n\u0131n planland\u0131\u011f\u0131n\u0131 ifade etti.<\/p>\n
\u2018KANSER TEDAV\u0130S\u0130NDE YEN\u0130 D\u00d6NEM: HASSAS \u00d6NLEME\u2019<\/p>\n
Do\u00e7. Dr. Ferhato\u011flu, bu yakla\u015f\u0131m\u0131n \u2018precision prevention\u2019 yani hassas \u00f6nleme stratejisinin \u00f6nemli bir \u00f6rne\u011fi oldu\u011funu vurgulayarak \u201cBu y\u00f6ntem yaln\u0131zca tedavi de\u011fil, kanseri olu\u015fmadan engellemeye y\u00f6nelik yeni bir d\u00f6nemin kap\u0131s\u0131n\u0131 aral\u0131yor\u201d dedi.<\/p>\n
\u00a0<\/p>\n
\u00a0<\/p>\n
Kaynak: (BYZHA) Beyaz Haber Ajans\u0131<\/p>\n","protected":false},"excerpt":{"rendered":"
T\u0131bbi Onkoloji Uzman\u0131 Do\u00e7.<\/p>\n","protected":false},"author":1,"featured_media":5867,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[31],"tags":[],"class_list":["post-5866","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-saglik"],"_links":{"self":[{"href":"https:\/\/ekonomievreni.com\/index.php?rest_route=\/wp\/v2\/posts\/5866","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ekonomievreni.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ekonomievreni.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ekonomievreni.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/ekonomievreni.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=5866"}],"version-history":[{"count":1,"href":"https:\/\/ekonomievreni.com\/index.php?rest_route=\/wp\/v2\/posts\/5866\/revisions"}],"predecessor-version":[{"id":5868,"href":"https:\/\/ekonomievreni.com\/index.php?rest_route=\/wp\/v2\/posts\/5866\/revisions\/5868"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ekonomievreni.com\/index.php?rest_route=\/wp\/v2\/media\/5867"}],"wp:attachment":[{"href":"https:\/\/ekonomievreni.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=5866"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ekonomievreni.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=5866"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ekonomievreni.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=5866"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}